Thndr Claps
  • Egypt
  • Saudi
  • Thinkers
  • العربية
No Result
View All Result
Thndr Claps

Thndr Claps » EGY Claps » Health & Pharma 👩‍⚕️ » Rameda to Start Producing COVID-19 Pill💊

Rameda to Start Producing COVID-19 Pill💊

by Shams Abbas
January 17, 2022

Rameda (RMDA) announced it will start production of the antiviral drug “Molnupiravir Rameda” after it obtained the necessary licenses from the Egyptian Drug Authority (EDA).

More on Molnupiravir💊 Molnupiravir is an antiviral drug approved for the treatment of adult infections with COVID-19. The pill was co-developed by U.S. pharmaceutical giant Merck & Co.

Pfizer had also announced that it is in discussions with 90 countries over supply contracts for its own pill, Paxlovid.

More Details🧐 Rameda is coordinating its production plans with the EDA & the Ministry of Health to ensure that market needs for this drug are met in a timely manner.

The first batch is expected before the end of Q1-2022 at a price of EGP 625/package, with each package containing 40 capsules & a concentration of 200 mg/capsule. 

Why is this Important🤔 The addition of Molnupiravir to Rameda’s portfolio will result in an expansion of its share in the fast-growing antiviral market. Rameda’s antiviral drugs contributed 12% to its total revenue during the first nine months of 2021.

RMDA closed 5.53% in the green in yesterday’s trading session.

  • Click to share on Facebook (Opens in new window)
  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)

Related Posts

Ibnsina Pharma close to launching Al Shorouk Hospital 🚪
Health & Pharma💉

Ibnsina signs 3 contracts for medical advertising

by Shams Abbas
June 15, 2023
الحكومة قامت بطرح عدد من مستشفيات القطاع الحكومي، اللي ببتتبع وزارة الصحة، علشان تبقى فرص للاستثمار من القطاع الخاص، بحسب تصريحات حسام عبد الغفار، متحدث وزارة الصحة.، ثاندر كلابس
Health & Pharma💉

Investors’ eyes on two state-owned pharma companies

by Shams Abbas
June 12, 2023
IDH profits decline; announces cash dividends
Health & Pharma💉

Integrated Diagnostics Holding’s profits fall 46% in Q1

by Shams Abbas
June 8, 2023
PIF has an appetite for Rameda  😋
Health & Pharma💉

Rameda strengthens its product lineup by acquiring 11 new products

by Shams Abbas
June 1, 2023
Health & Pharma💉

Ibnsina Pharma’s Q1-2023 profits jump 22%

by Shams Abbas
May 23, 2023
Health & Pharma💉

Macro Group’s profits decrease by 69% in Q1-2023

by Shams Abbas
May 17, 2023

Website

Community

Blog

Learn

© Thndr. All rights reserved

No Result
View All Result
  • Egypt
  • Saudi
  • Thinkers
  • العربية

Disclaimer: Thndr does not provide investment advice, individual investors are responsible for their own decisions or can seek independent advice. The value of investments can go up and down. Thndr is a trading name of Thndr Securities Brokerage which is authorised and regulated by the Financial Regulatory Authority (FRA). Registered in Egypt (no. 804)..© Thndr. All rights reserved

 

Hello👋 We want you to be able to express your opinions on anything and everything finance and economics related to the Egyptian and US markets.

This is why we introduced Thndr Thinkers💭

Let’s go through some housekeeping notes before you jump into publishing your article to all Thndr Claps readers!

Type of Content📝 We want to see market-relevant content that shows good analysis, please! Base your articles on facts 

Don’t be shy, explain🗣 Flex your knowledge to us, and we’ll share it with all the readers!

Be Original🙏 Please don’t copy. No one likes a copycat. All submissions are welcome as long as they’re yours 

Make your title attractive🤩 A title is like the cover of your book. Attractive enough to make you look at the book but also clear enough to tell you what the book is about.

Clean🧹 We’re all humans and we all make mistakes. But please try and clean up the article so it’s clear for all the readers 

No promotional content🚫 We don’t publish promotional content.

Any questions about becoming a Thndr Thinker? Email thndrclaps@thndr.app and we’d be happy to help!

Normally, your article will be published within 24 hours of submission (if you followed the guidelines)